Fingerprick blood samples to measure serum natalizumab concentrations. (March 2023)

• Record Type: Journal Article
• Authors: Toorop, Alyssa A; Steenhuis, Maurice; Loeff, Floris C; Weijers, Suzanne S; Killestein, Joep; Rispens, Theo; Kempen, Zoé LE van
• Is Part Of: Multiple sclerosis. Volume 29:Number 3(2023)
• Page Start: 457
• Page End: 460
• Publication Date: 2023-03
• Subjects: Multiple sclerosis -- natalizumab -- capillary -- fingerprick -- extended interval dosing; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/13524585221136448
• Languages: English
• ISSNs: 1352-4585

Abstract

Background: Natalizumab via subcutaneous administration was recently approved for patients with multiple sclerosis. Objective: In light of personalized extended dosing, in which treatment intervals are prolonged to a concentration cut-off, it would be preferable to measure natalizumab drug concentrations in capillary blood. Methods: In this cross-sectional study in patients treated with intravenous (IV) natalizumab, capillary blood samples by fingerprick and venous blood samples were collected in 30 participants prior to IV administration of natalizumab. Results: Natalizumab concentrations were similar with a mean bias of −0.36 μg/mL (95% CI: 1.3 to −2 μg/mL). Conclusions: This study shows that physicians can monitor natalizumab drug concentrations by a fingerprick, which could be used for personalized extended dosing.